Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

U.S. FDA Approves Gilead’s Second TAF-Based Single Tablet Regimen Odefsey for the Treatment of HIV-1 Infection

– Odefsey is the Smallest Single Tablet HIV Regimen –   FOSTER CITY, Calif.–(BUSINESS WIRE)– Gilead Sciences, Inc. (GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Odefsey® (emtricitabine 200 mg/rilpivirine 25 mg/tenofovir alafenamide 25 mg or R/F/TAF) for the treatment of HIV-1 infection in certain patients. Emtricitabine and tenofovir alafenamide […]

Read More »

Novo Nordisk and AstraZeneca seek tonic from key drug trials

Novo Nordisk and AstraZeneca, two drugmakers whose financial outlooks disappointed investors last month, are both hoping for a boost in the coming weeks from results of two closely watched clinical trials.   AstraZeneca wants to prove its blood-thinner Brilinta can help stroke patients, in addition to those with heart problems, while Novo aims to showcase the […]

Read More »

Multiple Failed Trials Lead Chimerix to Slash 20% of Workforce

In light of three failed clinical trials and disappointing financial statements, Durham, N.C.-based Chimerix (CMRX) cut about 20 percent of its workforce.   Chimerix focuses on the development of antiviral medications. At its recent fourth-quarter financial statements, the company reported a net loss of $117.4 million, or $2.67 per basic and diluted share for last […]

Read More »

AstraZeneca sells drug for $70 million as divestment drive continues

AstraZeneca has sold rights to a non-core drug to a unit of Kyowa Hakko Kirin for an upfront payment of $70 million, a day after getting $500 million for two ageing heart medicines.   The British-based drugmaker has been divesting peripheral products to help pay the bills as it invests in new medicines, while taking […]

Read More »

Comeback Kid Exelixis Wrangles Cancer Deal Worth $855 Million with Ipsen

March 1, 2016By Mark Terry, Breaking News Staff   South San Francisco-based Exelixis, Inc. (EXEL) and Paris-based Ipsen (IPN.PA) announced yesterday that they had inked an exclusive licensing agreement to commercialize and develop cabozantinib, Exelixis’ lead cancer drug. Ipsen will gain exclusive rights to commercialize cabozantinib for current and future indications outside the U.S., […]

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

June 2019 Focus: Payer access, biotech/biopharma, DTC, rare diseases, and more!


Ad Right Bottom